Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 30, 1988BMJOpen Access

Secondary prevention of vascular disease by prolonged antiplatelet treatment

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does antiplatelet treatment reduce vascular mortality and non-fatal vascular events in patients with a history of transient ischaemic attack, occlusive stroke, unstable angina, or myocardial infarction?

Population

29,000 patients from 25 randomised trials with a history of transient ischaemic attack, occlusive stroke…

Comparison

Antiplatelet treatment vs Control group (implied from randomised trials)

Design

Meta-analysis, Randomised trials

Discussion

Loading...

Member takes

Implication

Supports routine antiplatelet use for secondary prevention after TIA, stroke, or MI; confirms substantial vascular risk reduction in Level 1 meta-analysis.

Structured PICO

Does antiplatelet treatment reduce vascular mortality and non-fatal vascular events in patients with a history of transient ischaemic attack, occlusive stroke, unstable angina, or myocardial infarction?

P
Population
29,000 patients from 25 randomised trials with a history of transient ischaemic attack, occlusive stroke, unstable angina, or myocardial infarction
I
Intervention
Antiplatelet treatment (including 300-325 mg aspirin daily, higher aspirin doses, sulphinpyrazone, or high dose aspirin with dipyridamole)
C
Comparator
Control group (implied from randomised trials)
O
Outcome
Vascular mortality and non-fatal vascular events (stroke or myocardial infarction)hard clinical

Antiplatelet therapy significantly reduces vascular mortality and non-fatal vascular events by about a quarter in patients with a history of occlusive vascular disease.

Cite This Study

A 1988 study studied this question.

synapsesocial.com/papers/6a7d8933d0946debe914fdc9https://doi.org/10.1136/bmj.296.6618.320
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1"AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia.1983 · 612 citations
  2. 2A Randomized Trial of Aspirin and Sulfinpyrazone in Threatened Stroke1978 · 961 citations
  3. 3Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group.1980 · 470 citations
  4. 4High-dose acetylsalicylic acid after cerebral infarction. A Swedish Cooperative Study.1987 · 182 citations
  5. 5A Randomized, Controlled Trial of Aspirin in Persons Recovered From Myocardial Infarction1980 · 483 citations